Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2016-09-06 Legal Proceedings Report
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 6, 2016, announcing a specific business development: a German insurance company (AOK Bremen/Bremerhaven) agreeing to reimburse Theraclion's echotherapy treatment. This is a corporate announcement regarding market access and commercial progress, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). It fits best under the general category of corporate news or regulatory/market updates that don't fit other specific financial reporting codes. Since it is a specific announcement about market access and partnership, and not a general regulatory filing (RNS), it is best classified as a general announcement. Given the provided options, and since it is a specific business update that isn't a formal financial report, dividend notice, or management change, the most appropriate general category is Regulatory Filings (RNS) as a catch-all for significant, non-standard announcements, or potentially a Legal/Contractual update if the focus was on the agreement itself. However, RNS is the designated fallback for miscellaneous filings. Given the content is a press release announcing a commercial agreement, RNS is the most suitable fit among the choices for a non-standard corporate announcement.
2016-09-06 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated September 6, 2016, announcing that a German insurance company (AOK) has agreed to cover the cost of Theraclion's echotherapy treatment. This type of announcement, detailing a specific business development, market access achievement, or partnership, is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). It is not a formal financial report (10-K, IR), a management discussion (MDA), or a proxy statement (DEF 14A). Since it is a specific, non-financial operational announcement, RNS is the most appropriate general regulatory category, although it could also be considered a type of Investor Presentation material if it were part of a broader investor relations package, but as a standalone press release, RNS is safer.
2016-09-06 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 90% confidence The document is a press release dated August 31, 2016, announcing that Theraclion presented clinical data from five studies at the 5th International Symposium on Focused Ultrasound (FUS) and that the FDA cleared an IDE study request. The content focuses on clinical results, medical procedures, and company updates related to their Echopulse system. This type of announcement, detailing recent scientific presentations and regulatory milestones, is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a more specific category like a formal financial report (10-K, IR) or a management discussion (MDA). Since it is announcing positive clinical data and regulatory progress, it functions as an update to investors, making 'Earnings Release' (ER) the most appropriate fit among the options, as these often include operational and clinical highlights outside of pure financial figures, especially for smaller/biotech companies. It is not a transcript (CT), a formal report (10-K, IR), or a management report (MDA). Given the context of presenting data at a symposium, it is a form of operational/clinical update release. FY 2016
2016-08-31 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 92% confidence The document is a press release dated August 31, 2016, from Theraclion announcing positive clinical data for its Echopulse system presented at the FUS Symposium and the FDA's approval to start an IDE study. It details results from multiple ongoing studies on breast fibroadenomas and thyroid nodules. This content structure—announcing recent developments, clinical data presentation, and regulatory milestones in a news format—is characteristic of an Earnings Release (ER) or a general press announcement. Since it is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific management discussion (MDA), and it focuses on recent operational/clinical news rather than just financial results highlights, it fits best as a general announcement. Given the options, it is a press release detailing recent company activities and data presentation, which often overlaps with an Earnings Release (ER) if it were tied to a reporting period, but here it is a standalone clinical/regulatory update. However, since it is a detailed announcement of clinical progress and regulatory news, and not a formal financial report, it is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the depth of clinical data presented, it functions as a major operational update. In the context of financial reporting databases, such detailed clinical/regulatory updates are often categorized under ER if they are significant, or RNS if they are purely regulatory. Since it is a press release announcing clinical validation and FDA progress, ER is a strong candidate for significant operational news, but RNS is the general fallback for non-standard announcements. Given the content is a detailed press release about clinical data and FDA progress, and not a formal financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for a non-standard, non-financial-report press release.
2016-08-31 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated August 18, 2016, announcing the successful completion of a capital increase ('augmentation de capital') for Theraclion, detailing the gross amount raised (€9,629,337) and the number of new shares issued. The content focuses entirely on fundraising, financing structure reinforcement, and the allocation of shares. This directly corresponds to the definition of 'Capital/Financing Update'. Although it mentions a prospectus filed with the AMF, the document itself is the announcement of the capital operation, not the prospectus or a general regulatory filing fallback. Therefore, the most specific and accurate classification is CAP.
2016-08-18 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release announcing a capital increase ('augmentation de capital') involving the issuance of new shares ('actions nouvelles') with preferential subscription rights ('droit préférentiel de souscription'). It details the terms (price, parity, period) and the expected proceeds. This clearly falls under the category of financing activities and capital structure changes. Therefore, the appropriate code is 'CAP' (Capital/Financing Update). The document is a full announcement, not just a notice of publication (RPA) or a general regulatory filing (RNS).
2016-07-23 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.